Qlucore AB (publ) (NOVKAN) - Total Liabilities

Latest as of December 2025: Skr1.67 Million SEK ≈ $179.61K USD

Based on the latest financial reports, Qlucore AB (publ) (NOVKAN) has total liabilities worth Skr1.67 Million SEK (≈ $179.61K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Qlucore AB (publ) growing its equity to track the company's year-over-year net asset growth rate.

Qlucore AB (publ) - Total Liabilities Trend (2010–2025)

This chart illustrates how Qlucore AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Qlucore AB (publ) to measure how efficiently the company converts operating cash flow to free cash.

Qlucore AB (publ) Competitors by Total Liabilities

The table below lists competitors of Qlucore AB (publ) ranked by their total liabilities.

Company Country Total Liabilities
GCL Global Holdings Ltd Warrants
NASDAQ:GCLWW
USA $123.85 Million
LogicMark Inc
NASDAQ:LGMK
USA $2.03 Million
New Destiny Mining Corp
V:NED
Canada CA$2.49 Million
Sosandar Plc
LSE:SOS
UK GBX11.14 Million
Dewhurst plc
LSE:DWHA
UK GBX10.81 Million
Sanco Industries Limited
NSE:SANCO
India Rs687.89 Million
Mitra Komunikasi Nusantara Tbk PT
JK:MKNT
Indonesia Rp462.55 Billion
Cordel Group PLC
LSE:CRDL
UK GBX1.16 Million

Liability Composition Analysis (2010–2025)

This chart breaks down Qlucore AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Qlucore AB (publ) (NOVKAN) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 10.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.11 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.10 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Qlucore AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Qlucore AB (publ) (2010–2025)

The table below shows the annual total liabilities of Qlucore AB (publ) from 2010 to 2025.

Year Total Liabilities Change
2025-12-31 Skr1.67 Million
≈ $179.61K
-63.80%
2024-12-31 Skr4.61 Million
≈ $496.22K
-74.35%
2023-12-31 Skr17.98 Million
≈ $1.93 Million
+30.03%
2022-12-31 Skr13.83 Million
≈ $1.49 Million
+27.19%
2021-12-31 Skr10.87 Million
≈ $1.17 Million
+0.47%
2020-12-31 Skr10.82 Million
≈ $1.16 Million
-59.83%
2019-12-31 Skr26.93 Million
≈ $2.90 Million
+121.21%
2018-12-31 Skr12.18 Million
≈ $1.31 Million
-2.70%
2017-12-31 Skr12.51 Million
≈ $1.35 Million
-7.35%
2016-12-31 Skr13.51 Million
≈ $1.45 Million
+146.21%
2015-12-31 Skr5.49 Million
≈ $590.38K
-39.92%
2014-12-31 Skr9.13 Million
≈ $982.64K
+36.43%
2013-12-31 Skr6.69 Million
≈ $720.27K
-49.18%
2012-12-31 Skr13.17 Million
≈ $1.42 Million
-4.82%
2011-12-31 Skr13.84 Million
≈ $1.49 Million
+370.04%
2010-12-31 Skr2.94 Million
≈ $316.82K
--

About Qlucore AB (publ)

ST:NOVKAN USA Biotechnology
Market Cap
$326.04K
Skr3.03 Million SEK
Market Cap Rank
#31072 Global
#6200 in USA
Share Price
Skr0.03
Change (1 day)
-43.95%
52-Week Range
Skr0.03 - Skr0.23
All Time High
Skr0.23
About

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study… Read more